Liippo K, Tala E, Puolijoki H, Brückner O J, Rodrig J, Smits J P
Paimio Hospital, Preitilä, Finland.
J Infect. 1994 Mar;28(2):131-9. doi: 10.1016/s0163-4453(94)95540-9.
Dirithromycin, a new once-daily macrolide, was studied in a multicentre, randomised, double-blind trial in community-acquired bacterial pneumonia. A total of 591 patients received either a single daily dose of dirithromycin, 500 mg, or erythromycin, 250 mg, four times daily. Clinical response rates were similar in both treatment groups (127 dirithromycin-treated and 118 erythromycin-treated patients): at the time of the final consultation, the clinical and bacteriological response rates for dirithromycin-treated patients were 94.5% and 93.0%, while for erythromycin-treated patients, they were 92.1% and 90.3%, respectively. The nature and frequency of treatment-emergent events were comparable. We conclude that dirithromycin, 500 mg, once daily, is safe and effective in the treatment of community-acquired bacterial pneumonia. The once daily dose is likely to improve compliance, making it preferable to erythromycin.
地红霉素是一种新型的每日一次大环内酯类药物，在一项关于社区获得性细菌性肺炎的多中心、随机、双盲试验中进行了研究。共有591例患者接受治疗，其中一组每日单次服用500mg地红霉素，另一组每日4次服用250mg红霉素。两个治疗组的临床有效率相似（地红霉素治疗组127例，红霉素治疗组118例）：在最后一次会诊时，地红霉素治疗组的临床和细菌学有效率分别为94.5%和93.0%，而红霉素治疗组分别为92.1%和90.3%。治疗中出现的事件的性质和频率相当。我们得出结论，每日一次服用500mg地红霉素治疗社区获得性细菌性肺炎是安全有效的。每日一次给药可能会提高依从性，因此比红霉素更可取。
